Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Conexeu Sciences Inc. (CNXU)

2.5400 -0.2900 (-10.25%)
At close: October 30 at 4:00:01 PM EDT
2.6448 +0.1048 (+4.13%)
After hours: October 30 at 6:18:23 PM EDT
Chart Range Bar
Loading chart for CNXU
  • Previous Close 2.8300
  • Open 2.8500
  • Bid 2.8000 x 100
  • Ask 4.0700 x 100
  • Day's Range 2.4300 - 2.8500
  • 52 Week Range 2.4300 - 18.7900
  • Volume 518,841
  • Avg. Volume 280,925
  • Market Cap (intraday) 78.313M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6100
  • Earnings Date (est.) Jan 22, 2027
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 20.00
  • Zacks Rating Neutral

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

www.conexeu.com

--

Full Time Employees

October 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNXU
81.19%
S&P 500 (^GSPC)
10.73%

1-Year Return

CNXU
81.19%
S&P 500 (^GSPC)
11.11%

3-Year Return

CNXU
81.19%
S&P 500 (^GSPC)
81.91%

5-Year Return

CNXU
81.19%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -7.73M
Profit Margin 0.00%

Q3

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

20.00
20.00 Average
2.5400 Current
20.00 High

Latest Rating

Date 6/22/2026
Analyst HC Wainwright & Co.
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 20

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -170.73%

  • Return on Equity (ttm)

    -332.93%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -13.63M

  • Diluted EPS (ttm)

    -0.6100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.97M

  • Total Debt/Equity (mrq)

    7.76%

  • Levered Free Cash Flow (ttm)

    -5.4M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: